ACAD (ACADIA Pharmaceuticals) Current Accrued Expense: $267 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ACAD ACADIA Pharmaceuticals Inc ACAD
82 GF Score
Price $29.22
GF Value $24.92
Valuation Modestly Overvalued
! 10 Warning Signs
View Full Analysis

What is ACADIA Pharmaceuticals Current Accrued Expense?

ACADIA Pharmaceuticals ACAD +2.64% 82 Current Accrued Expense is $267 Mil as of Jun. 2026. GuruFocus rates ACAD with a GF Score™ of 82/100 and a GF Value™ of $24.92 (Modestly Overvalued). The stock has 10 warning signs investors should review.

ACADIA Pharmaceuticals's Current Accrued Expense for the quarter that ended in Jun. 2026 was $267 Mil.

ACADIA Pharmaceuticals's quarterly Current Accrued Expense increased from Dec. 2025 ($209 Mil) to Mar. 2026 ($250 Mil) and increased from Mar. 2026 ($250 Mil) to Jun. 2026 ($267 Mil).

ACADIA Pharmaceuticals's annual Current Accrued Expense increased from Dec. 2023 ($183 Mil) to Dec. 2024 ($320 Mil) but then declined from Dec. 2024 ($320 Mil) to Dec. 2025 ($209 Mil).

ACADIA Pharmaceuticals Current Accrued Expense Related Terms

ACADIA Pharmaceuticals Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for ACADIA Pharmaceuticals's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACADIA Pharmaceuticals Current Accrued Expense Chart

ACADIA Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 54.99 75.18 183.02 320.15 208.70

ACADIA Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 269.46 285.24 208.70 250.06 267.22
ACAD
82GF Score
ACADIA Pharmaceuticals Inc ACAD
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ACADIA Pharmaceuticals Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $267 Mil mean?
ACADIA Pharmaceuticals (ACAD) has a Current Accrued Expense of $267 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on ACADIA Pharmaceuticals and its competitors.
Is ACADIA Pharmaceuticals' Current Accrued Expense too high?
ACADIA Pharmaceuticals' current Current Accrued Expense is $267 Mil. Overall, ACADIA Pharmaceuticals has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' Current Accrued Expense compare to LEGN and TNGX?
ACADIA Pharmaceuticals' Current Accrued Expense of $267 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on ACADIA Pharmaceuticals and its competitors. ACADIA Pharmaceuticals's current Current Accrued Expense is $267 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (ACAD) is currently considered Modestly Overvalued. The stock's GF Value™ is $24.92, compared to a current price of $29.22 — trading 17.3% above its estimated fair value. The current Current Accrued Expense is $267 Mil. ACADIA Pharmaceuticals' overall GF Score™ is 82/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For ACADIA Pharmaceuticals (ACAD), the current Current Accrued Expense is $267 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ACADIA Pharmaceuticals (ACAD) Overvalued in 2026?

Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be overvalued. The current stock price of $29.22 is trading 17.3% above its estimated GF Value™ of $24.92. GuruFocus considers ACADIA Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for ACAD:

  • Current Accrued Expense: $267 Mil
  • GF Value™: $24.92 vs. price of $29.22 (17.3% above fair value)
  • GF Score™: 82/100 with 10 warning signs

No single metric tells the full story. See the ACAD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ACADIA Pharmaceuticals Business Description

Other Exchanges ACAD:MexicoDR6:Germany
Address 12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
82GF Score

Get the complete analysis for ACAD

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.22
Price
$24.92
GF Value